The use of autologous mesenchymal stem cells in Amyotrophic Lateral Sclerosis (ALS) represents a promising avenue of research and a potential treatment for this devastating neurodegenerative disease. Autologous mesenchymal stem cells are derived from a patient’s own bone marrow, ensuring compatibility and eliminating the risk of rejection. In ALS, the stem cells have demonstrated the potential to restore the blood-spinal cord barrier, reduce inflammation, supply growth factors, and protect nerves in the spinal cord. Preclinical research in ALS has shown encouraging results, where autologous mesenchymal stem cells have slowed disease progression and increased survival.
NECTx’s autologous mesenchymal stem cell therapy, STR04, is based on Stemirac®, which has conditional approval in Japan for the treatment of spinal cord injury. NECTx’s autologous mesenchymal stem cell therapy is investigational and not FDA approved.
Learn More
